X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home IPR Data Management

AI In Pharma: Possibility European Regulators Look To Propel

Content Team by Content Team
22nd December 2023
in IPR Data Management, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The European Medicines Agency- EMA and the Heads of Medicines Agencies- HMAs have gone on to publish a plan that helps to set out a collaborative as well as coordinated strategy so as to maximize the advantages of artificial intelligence- AI in regulation.

The workplan, which happens to run until 2028, will go on to help the European medicines regulatory network- EMRN take up the opportunities of AI when it comes to personal productivity, automating processes along with systems, growing insights into data, as well as supporting stronger decision-making in order to benefit public and also animal health.

The plan happened to be prepared by the Big Data Steering Group- BDSG which is a joint initiative between HMA and EMA. The objective of this steering group is to make sure that the EMRN continues to be at the forefront of benefiting from AI when it comes to medicine regulation.

Apparently, the document was adopted by EMA’s Management Board at its meeting in December.

Four key dimensions when it comes to the AI workplan

It is well to be noted that the first version of the BDSG multi-annual workplan focuses on four areas so as to facilitate the development as well as use of responsible and beneficial AI.

Guidance and policy, along with product support: Actions focus on consistent support for products in development, along with the development and evaluation of apt guidance for the usage of AI in the lifecycle of a medicine. Work has already started with the ongoing public consultation when it comes to the AI reflection paper, which is open until the end of 2023. Preparations so as to support the implementation of the EU AI Act will begin in 2024.

AI tools and technology: The idea is to identify as well as provide frameworks so as to use AI tools to grow efficiency, elevate understanding and evaluation of data, and support decision-making. Complete compliance when it comes to data protection legislation will be ensured.

Training and partnership: Initiatives happen to be designed so as to continuously develop the capacity as well as capability of the network, partners, along with stakeholders so as to keep ahead of the evolving field of AI.

Experimentation: The workplan considers the fundamental role of experimentation when it comes to experimentation in speeding-up learning and also gaining new insights. Numerous actions are proposed so as to make sure of a structured approach to experimentation throughout the network.

Because of the fast evolution of AI technology such as the ethical and policy aspects that are related to it, the Big Data Steering Group looks to regularly update the workplan.

Previous Post

Global Advanced Empty Capsules To See A Growth of 7.4% CAGR

Next Post

Drug Development Benchmarks Driven By Quality By Design

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post

Drug Development Benchmarks Driven By Quality By Design

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In